Spotlight On... Kannalife considers an IPO; Biotech stalwart Mann dies at 90; and more...

New York biotech Kannalife Sciences is weighing an IPO in hopes of bankrolling its work on a cannabis-based treatment for a rare brain disorder. As Reuters reports, the company has a preclinical therapy for hepatic encephalopathy, a disease caused by blood toxins reaching the brain and affecting cognitive function. The plan, Kannalife said, is to raise between $5 million and $10 million in a mezzanine round before starting down the road to an IPO, according to Reuters. News

@FierceBiotech: Charities and pharma decry 'disgraceful' changes to England's Cancer Drugs Fund. Story | Follow @FierceBiotech

@JohnCFierce: Glad to see the top trending story yesterday was the Exicure profile. Doesn't always happen with little biotechs. Story | Follow @JohnCFierce

@DamianFierce: Wired is getting into dystopian fiction. Wired story | Follow @DamianFierce

> Longtime biotech entrepreneur Al Mann, founder of MannKind ($MNKD), has died at the age of 90. Story

> Peregrine Pharmaceuticals' ($PPHM) shares fell more than 60% after the company's lung cancer therapy bavituximab failed in Phase III. Item

Medical Device News

@FierceMedDev: ICYMI: Boston Scientific's Brazilian operations under investigation, as co-founder to depart. Story | Follow @FierceMedDev

@EmilyWFierce: Intel hops on the precision medicine bandwagon with new projects for 2016. News | Follow @EmilyWFierce

> FDA warns of unintentional head movement during surgery despite use of skull clamp. Story

> Boston upstart raises $46M, makes acquisition for translational imaging in biopharma R&D. More

Pharma News

@FiercePharma: Look out, drugmakers: NICE is taking the reins of England's Cancer Drugs Fund. Story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Short on label expansions, Pfizer nabs FDA OK for new, once-daily Xeljanz. Story | Follow @CarlyHFierce

> Opdivo wins thumbs up from CHMP for two indications, in lung and kidney cancers. News

> Analyst: Valeant better bring back Pearson if it wants to stay in the game. More

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

U.K.-based alpha-synuclein biotech Wren will partner with Japanese pharma Eisai to seek out new ways of targeting neuro disorders.

As Moderna continues to drip-feed the latest data from its late-stage COVID-19 vaccine effort, it has updated the shot’s efficacy figure.

Two research teams have discovered drug combinations that may make it possible to translate CAR-T cell therapies to solid tumors.